RHYTHMONE
11.9.2019 07:32:09 CEST | Business Wire | Press release
RhythmOne , LLC, a Tremor International company, today announces it will be bringing the infrastructure, scale and success of its programmatic platform to the Asia-Pacific (APAC) and Latin American (LATAM) markets. The announcement will also be made at the international digital marketing conference DMEXCO, following the company’s successful expansion into Europe earlier this year.
To lead international expansion efforts, today the company also announces the appointment of industry veterans Assaf Suprasky as General Manager of Tremor International’s Israel operations and Gal Topaz as Senior Vice President, Exchange Operations and Business Development. Both executives come to RhythmOne with deep experience in advanced mobile and digital video advertising solutions. Prior to his role at RhythmOne, Suprasky was CEO at personalized advertising specialist myThings, and Topaz was the CEO of programmatic group Feature Forward. Physical business development and sales teams are also now in place and active in Europe, APAC, and LATAM.
The RhythmOne Programmatic Platform is among the world’s largest brand-safe programmatic platforms. Offering technological efficiency at virtually every stage of the process, the global platform helps to effectively connect buyers to sellers and engage consumers on formats spanning video, connected TV (CTV), in-app, and display. A proven leader in the US, the RhythmOne Programmatic Platform reaches 358.8 million uniques globally* and is directly integrated with 600+ premium publishers – resulting in over 10,000 properties. The April 2019 acquisition of RhythmOne by Tremor International (AIM: TRMR) has laid the groundwork for further expansion initiatives and enhancements to the platform, including leveraging the large geographical footprint of the group’s performance division by expanding the RhythmOne Programmatic Platform into Asia.
With brand safety at the heart of its offering – supported by RhythmGuard, RhythmOne’s proprietary brand safety technology – and consistent top-tier ratings in Pixalate’s Seller Trust Indexes for programmatic display, mobile, and video advertising both internationally and in the US, the RhythmOne Programmatic Platform helps deliver high-quality solutions with large scale, and is integrated with the major international players including Google Exchange Bidding and Amazon A9. For publishers, RhythmOne offers a fully-integrated supply monetization platform (SSP) to maximize the value of inventory across desktop, mobile, and connected TV devices. Powered by an enhanced technology stack, the RhythmOne SSP provides web publishers and app developers with full access to a global programmatic ad marketplace.
“We are proud to be hosting a large-scale presence at DMEXCO this year as we take our US success and bring it to the international stage in the Asia-Pacific and Latin American markets,” said Ofer Druker, CEO Tremor International. “Our platform has massive global reach, has unique features and partnerships, and, alongside our market-specific business development professionals, we provide the perfect combination of a world-class product with local support, giving us confidence in delivering our product on an international scale. We are also pleased to welcome Assaf Suprasky and Gal Topaz to the RhythmOne team and are confident that their expertise will help bolster our success by delivering results to both demand clients and supply partners on the global stage.”
*Quantcast Measure, August 2019 / 30 Day Total
-ENDS-
Notes to the editors
RhythmOne is top-rated in the most current Pixalate programmatic seller trust rankings (Q4 2018):
- #1 US and #4 International, Global Seller Trust Index
- #1 Mobile Seller Trust Index
- #1 US and #2 International, Video Seller Trust Index
Since 2018, RhythmOne has been partnered with AU-based Allegiant Media as a reseller for RhythmOne in Australia and New Zealand. RhythmOne will be continuing its partnership with them.
About Tremor International
Tremor International Ltd is a global leader in advertising technologies, operating in more than 70 countries. It has three core divisions: Tremor Video (brand advertising), RhythmOne (media) and Taptica (performance advertising).
RhythmOne drives real business outcomes in multiscreen advertising. Its highly-ranked programmatic platform efficiently and effectively delivers performance, quality, and actionable data to demand and supply-focused clients and partners – and its influencer marketing offering fosters action and awareness by connecting brands with influencers who create and distribute branded content to engaged consumers.
Tremor Video helps advertisers deliver impactful brand stories across all screens through the power of creative video intelligence—innovative video technology combined with advanced audience data and captivating creative. Tremor Video is one of the largest and most innovative video advertising companies in North America, with offerings in CTV, influencer marketing, and private marketplaces.
The Taptica performance business is an end-to-end mobile technology advertising platform that helps the world's top brands reach their most valuable users with the widest range of traffic sources available today. Its proprietary technology leverages big data to target quality media at scale. It works with more than 600 advertisers including Amazon, Alibaba, Bytedance, Netmarble, Stubhub and OpenTable.
Tremor International Ltd is headquartered in Israel and maintains offices throughout the US and Canada, Asia-Pacific, Europe, India, and Latin America, and is traded on the London Stock Exchange (AIM: TRMR).
Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," “likely,” "will," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. All statements other than statements of historical fact are statements that could be forward-looking statements, including, but not limited to, statements about the potential and effectiveness of RhythmOne’s programmatic platform. These forward-looking statements are subject to risks and uncertainties, assumptions and other factors that could cause actual results and the timing of events to differ materially from future results that are expressed or implied in the forward-looking statements. Factors that could cause or contribute to such differences include the dynamic and rapidly evolving sector, as well as the highly competitive industry that RhythmOne operates in, which make it difficult to evaluate prospects. These and other risk factors are discussed in RhythmOne’s Annual Report for the period ended March 31, 2018. The forward-looking statements in this article are based on information available to RhythmOne as of the date hereof, and we assume no obligation to update any forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005104/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
